Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Azenta Inc(AZTA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AZTA
10/26/2026: AZTA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Azenta Inc is a life sciences tools company that specializes in automated sample management and genomic services. By providing the critical infrastructure required for biological research, it has positioned itself as an important partner to the pharmaceutical and biotech industries. Its main strength lies in its integrated 'sample-to-insight' workflow, which offers recurring service revenue alongside hardware sales. Key risks include heavy dependence on biopharma research budgets and intense competition from large life science conglomerates. The stock may best suit growth-oriented investors looking for exposure to R&D trends; however, investors should monitor the company's ability to maintain margins and successfully execute its strategy amid sector-wide funding volatility.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Azenta is positioned in high-growth sectors of life science research and genomic services. |
| Momentum investor | Mixed fit | Performance is highly conditional on biopharma spending trends and market sentiment. |
| Value investor | Weak fit | The stock often trades at a premium valuation typical of growth-stage life science tools companies. |
| Dividend investor | Weak fit | The company does not currently pay a dividend. |
| Low-risk investor | Weak fit | The company is subject to sector volatility and R&D spending cycles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock is susceptible to changes in the biotechnology and pharmaceutical funding environment. |
| Valuation risk | Medium | Growth expectations are already baked into current pricing, leaving little room for earnings misses. |
| Competition risk (Life Sciences giants) | High | Large competitors with bundled service offerings can aggressively target Azenta's market segments. |
| Business quality | Medium | The company has a strong recurring revenue base in services but remains exposed to capital equipment cycles. |
| Dividend income | Low / none | Investors should not expect income generation from this stock. |
| Execution risk | Medium | Successfully integrating and scaling the diverse businesses acquired is critical for long-term margin improvement. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -21.66% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/26/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.60B USD | Price to earnings Ratio - | 1Y Target Price 37.8 |
Price to earnings Ratio - | 1Y Target Price 37.8 | ||
Volume (30-day avg) 1.1M shares | Beta 1.52 | 52 Weeks Range 15.93 - 46.41 | Updated Date 10/25/2026 |
52 Weeks Range 15.93 - 46.41 | Updated Date 10/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.47 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Sample Management | Automated freezers, consumables, and sample storage services for biotech firms. | Selling the hardware and services necessary to keep biological samples safe for long-term research. |
| Genomics Services | DNA/RNA sequencing and synthesis provided through the GENEWIZ brand. | Providing specialized lab services to analyze genetic material for researchers. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 29.07 | Enterprise Value 1.05B | Price to Sales(TTM) 2.61 |
Enterprise Value 1.05B | Price to Sales(TTM) 2.61 | ||
Enterprise Value to Revenue 1.71 | Enterprise Value to EBITDA 31.86 | Shares Outstanding 43.81M | Shares Floating 38.88M |
Shares Outstanding 43.81M | Shares Floating 38.88M | ||
Percent Insiders 1.34 | Percent Institutions 117.76 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.